John Henneman III Acquires 5,000 Shares of Orthofix Medical (NASDAQ:OFIX) Stock

Orthofix Medical Inc. (NASDAQ:OFIX) Director John Henneman III acquired 5,000 shares of Orthofix Medical stock in a transaction that occurred on Thursday, May 7th. The shares were purchased at an average cost of $12.26 per share, for a total transaction of $61,300.00. Following the purchase, the director directly owned 90,809 shares in the company, valued at $1,113,318.34. The trade was a 5.83% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Orthofix Medical Stock Down 3.5%

Orthofix Medical stock opened at $11.65 on Friday. The company’s 50 day simple moving average is $12.20 and its 200 day simple moving average is $13.88. Orthofix Medical Inc. has a fifty-two week low of $10.24 and a fifty-two week high of $16.99. The firm has a market capitalization of $467.63 million, a price-to-earnings ratio of -7.72 and a beta of 0.79. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.87 and a quick ratio of 1.43.

Orthofix Medical (NASDAQ:OFIX) last released its quarterly earnings data on Tuesday, May 5th. The medical device company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.16. Orthofix Medical had a negative net margin of 7.27% and a negative return on equity of 13.44%. The business had revenue of $196.71 million for the quarter, compared to analyst estimates of $196.40 million. As a group, sell-side analysts anticipate that Orthofix Medical Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Canaccord Genuity Group dropped their price objective on Orthofix Medical from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. TD Cowen began coverage on Orthofix Medical in a research note on Tuesday, January 27th. They set a “hold” rating and a $14.00 price objective on the stock. Wall Street Zen cut Orthofix Medical from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Stifel Nicolaus lowered their target price on Orthofix Medical from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Finally, Barrington Research reissued an “outperform” rating and set a $17.00 target price on shares of Orthofix Medical in a research note on Friday, April 10th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $17.25.

Orthofix Medical News Roundup

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Engine Capital Management, a major shareholder, bought about 184,900 shares of Orthofix Medical across May 5-7 for roughly $2.23 million, increasing its stake to about 3.85 million shares. That kind of repeated insider accumulation often signals confidence in the company’s outlook and can support the stock. Article: Insider Buying: Orthofix Medical (NASDAQ:OFIX) Major Shareholder Purchases 30,000 Shares of Stock
• Positive Sentiment: Orthofix posted first-quarter results that beat expectations, reporting a smaller-than-expected loss per share and revenue roughly in line with estimates. Investors may view the earnings beat as a sign that performance is holding up better than feared. Article: Orthofix Medical earnings report
• Neutral Sentiment: Analysts maintained a consensus view of roughly Hold, but the average price target is $17.25, which is above recent trading levels and suggests some upside if execution improves. Article: Orthofix Medical Inc. (NASDAQ:OFIX) Just Reported, And Analysts Assigned A US$17.25 Price Target
• Neutral Sentiment: Another report noted Engine Capital’s purchase of 30,000 shares for about $365,400, reinforcing the theme of insider confidence, though this is part of the same buying trend already reflected above. Article: Insider Buying: Orthofix Medical (NASDAQ:OFIX) Major Shareholder Purchases 30,000 Shares of Stock
• Negative Sentiment: Despite the earnings beat, Orthofix remains unprofitable and faces margin pressure, and the FDA’s reclassification of bone growth stimulators could increase competitive pressure in a key product category. Those issues may be limiting enthusiasm around the stock. Article: FDA reclassifies bone growth stimulators

Hedge Funds Weigh In On Orthofix Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. R Squared Ltd boosted its stake in Orthofix Medical by 7.2% in the 1st quarter. R Squared Ltd now owns 13,518 shares of the medical device company’s stock worth $155,000 after purchasing an additional 904 shares during the period. CWM LLC lifted its stake in Orthofix Medical by 99.0% in the 3rd quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock valued at $28,000 after acquiring an additional 955 shares in the last quarter. Gabelli Funds LLC lifted its stake in Orthofix Medical by 0.4% in the 4th quarter. Gabelli Funds LLC now owns 235,303 shares of the medical device company’s stock valued at $3,567,000 after acquiring an additional 1,000 shares in the last quarter. Raymond James Financial Inc. lifted its stake in Orthofix Medical by 1.5% in the 3rd quarter. Raymond James Financial Inc. now owns 66,812 shares of the medical device company’s stock valued at $978,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Amundi lifted its stake in Orthofix Medical by 2.7% in the 4th quarter. Amundi now owns 41,527 shares of the medical device company’s stock valued at $630,000 after acquiring an additional 1,086 shares in the last quarter. 89.76% of the stock is owned by institutional investors and hedge funds.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.